Key Drivers
- Strong Liquidity
- Margin Compression
- Equity Dilution
AIAI Summary
TPB's modern oral-nicotine pivot offers meaningful growth upside, but at ~22x EBITDA investors should wait for evidence that ALP/FRE expansion restores margins and cash conversion, as intensifying competition and falling estimates leave little room for execution misses.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Margin Compression
- •Equity Dilution
TPB has strong liquidity and annual returns, but weakening quarterly profitability, reliance on equity financing, and high valuation multiples warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support test
- •Failed rebounds
TPB remains bearish over the last month with lower highs/lows, support at $68.10, and rebounds likely capped unless price reclaims $72.00 then $75.00–$77.00.
RSI near 74 signals a stretched short-term move
Sentiment & News
Key News Insights:
- •UK Market Entry
- •Intensifying Competition
- •Weak Estimate Trends
TPB is expanding ALP into the UK and Ireland to pursue oral-nicotine growth, but competitive pressure and weakening analyst estimates may constrain near-term sentiment.
The news is strategically positive for TPB's long-term growth, but near-term investor sentiment may remain pressured by competitive and analyst-ranking headwinds
Similar Companies in Consumer Defensive
Other companies in the same sector with AI ratings